Immunology

Gene therapy vaccine in development for cancer

Published in Vaccine Weekly, May 15th, 2002

T lymphocytes of the immune system are vital to bodily defenses against viruses and cancer. T lymphocytes are activated in part by molecules called costimulatory signals, of which 4-1BB is one example. However, tumor cells are cleverly able to turn off the effects of some costimulatory molecules, thus ensuring their own survival.

Recent experiments in mice have shown that binding a monoclonal antibody to 4-1BB activates this costimulatory molecule and triggers a strong immune response. Based on this knowledge, Karl Erik Hellstrom and colleagues at the Pacific Northwest Research Institute in Seattle have developed a form of gene therapy to treat cancer. They inserted...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry